VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival ...
Biotech Analyst Biegler, along with Dr Krishnamurthy, Associate Professor of Medicine & Co-Director of Breast Cancer Program at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback